Details of Drug-Drug Interaction
| Drug General Information (ID: DDIP46TGA0) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Peginterferon alfa-2a | Drug Info | Pegfilgrastim | Drug Info | |||||
| Drug Type | Interferons | Small molecule | |||||||
| Therapeutic Class | Antineoplastics | Immunomodulatory Agents | |||||||
| Mechanism of Peginterferon alfa-2a-Pegfilgrastim Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Peginterferon alfa-2a | Pegfilgrastim | |||||||
| Mechanism | Reduce therapeutic efficacy of hematopoietic growth factors | Hematopoietic growth factors | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA. | ||||||||||||||||||
| 2 | Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA. | ||||||||||||||||||